Assess whether to resubmit, meet, or pause the program

SITUATION In a company with a CMC site change mid-review, scientific-advice briefing book is the evidence after a pediatric ethicist objecting to the proposed design. Clinical-development physician has to pick To resubmit, meet, or Pause the program for this Pharma & Life Sciences FDA Response and Labeling close using scientific-advice briefing book.

DECISION Clinical-development physician in a company with a CMC site change mid-review must choose To resubmit, meet, / Pause the program using scientific-advice briefing book after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. The population in scientific-advice briefing book is the one a pediatric ethicist objecting to the proposed design named, so To resubmit, meet, follows for this FDA Response and Labeling file. 2. The population in scientific-advice briefing book is adjacent only to a pediatric ethicist objecting to the proposed design; Pause the program is the honest Pharma & Life Sciences call. 3. A company with a CMC site change mid-review already contained a pediatric ethicist objecting to the proposed design before scientific-advice briefing book arrived; no new FDA Response and Labeling path. 4. Provenance on scientific-advice briefing book after a pediatric ethicist objecting to the proposed design is broken; do not pick To resubmit, meet, or Pause the program yet.

ANALYSIS REQUIRED 1. Check whether scientific-advice briefing book supports the labeled claim clinical-development physician would keep. 2. Map FDA-response timing and owner in a company with a CMC site change mid-review. 3. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a pediatric ethicist objecting to the proposed design. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read scientific-advice briefing book against a pediatric ethicist objecting to the proposed design and write the one fact that would move to resubmit, meet, or for clinical-development physician.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / FDA Response and Labeling packet (scientific-advice briefing book after a pediatric ethicist objecting to the proposed design). If scientific-advice briefing book cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent missing evidence a company with a CMC site change mid-review does not have.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in scientific-advice briefing book, then the action for clinical-development physician - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Regulatory or exam hook FDA Response and Labeling would cite - FDA Response and Labeling finding in scientific-advice briefing book that a second reviewer can re-perform